The antimicrobial activities of cyclosporine, FK506, and rapamycin.
High
K P
KP
Section on Infectious Diseases, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina 27157-1042.
D000818:Animals; D000890:Anti-Infective Agents / Q000627:therapeutic use / Q000633:toxicity*; D000998:Antiviral Agents / Q000633:toxicity; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology; D001424:Bacterial Infections / Q000188:drug therapy; D016572:Cyclosporine / Q000627:therapeutic use / Q000633:toxicity*; D006678:HIV / Q000187:drug effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use / Q000633:toxicity*; D010272:Parasitic Diseases / Q000188:drug therapy; D011090:Polyenes / Q000627:therapeutic use / Q000633:toxicity*; D020123:Sirolimus; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D016559:Tacrolimus / Q000627:therapeutic use / Q000633:toxicity*; D014777:Virus Diseases / Q000188:drug therapy
D000890:Anti-Infective Agents; D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D011090:Polyenes; D016572:Cyclosporine; D020123:Sirolimus; D016559:Tacrolimus